A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma

In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment. The primary endpoint was progression-free survival at 6 months; secondary objectives were clinical re...

Descripción completa

Detalles Bibliográficos
Autores principales: Addeo, Raffaele, Caraglia, Michele, De Santi, M. Serena, Montella, Liliana, Abbruzzese, Alberto, Parlato, Ciro, Vincenzi, Bruno, Carraturo, Marco, Faiola, Vincenzo, Genovese, Michele, Cennamo, Gregorio, Del Prete, Salvatore
Formato: Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Clinical Study – Patient Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089727/
https://www.ncbi.nlm.nih.gov/pubmed/20694830
http://dx.doi.org/10.1007/s11060-010-0329-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089727/
https://www.ncbi.nlm.nih.gov/pubmed/20694830
http://dx.doi.org/10.1007/s11060-010-0329-z

Ejemplares similares